menu

NSCLC Therapy Management and Biomarker Testing

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

NSCLC Therapy Management and Biomarker Testing

1.00 credits
60 minutes

CME/CE Broadcast Replay

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Capitalizing on the advances in the identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapies are the current standard of care for eligible patients with advanced non–small cell lung cancer (NSCLC). Many targeted therapies are approved for the treatment of metastatic NSCLC with oncologic therapy decisions based on the presence of mutations and gene rearrangements. The National Comprehensive Cancer Center (NCCN) Clinical Practice Guidelines for metastatic NSCLC outline recommendations for molecular testing, now including EGFR mutation (for examples, exon 19 deletion or L858R), EGFR exon 20 insertion mutation, KRAS G12C mutation, ALK rearrangement, ROS1 rearrangement, BRAF-V600E mutation, NTRK1/2/3 gene fusion, METex14 skipping mutation, and RET rearrangement, along with PD-L1 expression level in patients with advanced or metastatic NSCLC. The development of these newer and other investigational targeted therapies provides unprecedented opportunities for improving outcomes for patients with targetable mutations.

    This educational activity will address the incorporation of appropriate and timely use of guideline-recommended biomarker testing and optimization of targeted and personalized treatment of patients with NSCLC.

    NCCN Guidelines have been updated since the release of this activity regarding ctDNA testing. The use of ctDNA testing is no longer considered only in specific clinical circumstances. Instead, data support complementary ctDNA and tissue testing to reduce turnaround time and increase yield of targetable alteration detection (NCCN Guidelines in NSCLC version 3.2024).

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Janssen Oncology, Jazz Pharmaceuticals plc, Guardant Health, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., and Lilly. Research grant; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Spectrum Pharmaceuticals, Inc., Daiichi-Sankyo, Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and BeiGene LTD. Consultant; OncoC4. Contracted research; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Spectrum Pharmaceuticals, Inc., Daiichi-Sankyo, Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and BeiGene LTD.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months: Linda Gracie-King, MS; Rosanne Strauss, PharmD, MBA; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C, and Dee Morgillo, MEd., MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Target Audience

    This educational activity is designed for medical oncologists, thoracic oncologists, pathologists/lab professionals, pulmonologists, surgeons, oncology nurses, nurse practitioners, pharmacists, physician assistants, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with NSCLC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify and review key oncogenic drivers of NSCLC
    • Integrate guideline-recommended strategies for biomarker analysis in advanced/metastatic NSCLC to identify potentially efficacious targeted therapies
    • Evaluate various biomarker testing methodologies and diagnostic assays to determine mutational status in advanced/metastatic NSCLC
    • Assess evidence for newer targeted therapy and immunotherapy options for the treatment of advanced/metastatic NSCLC with driver mutations
    • Apply evidence-based biomarker-guided therapy for advanced/metastatic NSCLC patients based upon the presence of oncogenic driver mutations
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

    Credit Designation for Pharmacists

    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-026-H01-P.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until July 15, 2023. PAs should only claim credit commensurate with the extent of their participation.

     

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-024-L01-P for June 27, 2023 and JA4008106-0000-23-025-L01-P for June 29, 2023.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by educational funding provided by Amgen.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Capitalizing on the advances in the identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapies are the current standard of care for eligible patients with advanced non–small cell lung cancer (NSCLC). Many targeted therapies are approved for the treatment of metastatic NSCLC with oncologic therapy decisions based on the presence of mutations and gene rearrangements. The National Comprehensive Cancer Center (NCCN) Clinical Practice Guidelines for metastatic NSCLC outline recommendations for molecular testing, now including EGFR mutation (for examples, exon 19 deletion or L858R), EGFR exon 20 insertion mutation, KRAS G12C mutation, ALK rearrangement, ROS1 rearrangement, BRAF-V600E mutation, NTRK1/2/3 gene fusion, METex14 skipping mutation, and RET rearrangement, along with PD-L1 expression level in patients with advanced or metastatic NSCLC. The development of these newer and other investigational targeted therapies provides unprecedented opportunities for improving outcomes for patients with targetable mutations.

    This educational activity will address the incorporation of appropriate and timely use of guideline-recommended biomarker testing and optimization of targeted and personalized treatment of patients with NSCLC.

    NCCN Guidelines have been updated since the release of this activity regarding ctDNA testing. The use of ctDNA testing is no longer considered only in specific clinical circumstances. Instead, data support complementary ctDNA and tissue testing to reduce turnaround time and increase yield of targetable alteration detection (NCCN Guidelines in NSCLC version 3.2024).

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form of Speakers' bureau; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Janssen Oncology, Jazz Pharmaceuticals plc, Guardant Health, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., and Lilly. Research grant; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Spectrum Pharmaceuticals, Inc., Daiichi-Sankyo, Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and BeiGene LTD. Consultant; OncoC4. Contracted research; Genentech, Inc., AstraZeneca Pharmaceuticals LP, Mirati Therapeutics, Spectrum Pharmaceuticals, Inc., Daiichi-Sankyo, Inc., Novartis Pharmaceuticals Corporation, Takeda Oncology, and BeiGene LTD.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months: Linda Gracie-King, MS; Rosanne Strauss, PharmD, MBA; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C, and Dee Morgillo, MEd., MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Target Audience

    This educational activity is designed for medical oncologists, thoracic oncologists, pathologists/lab professionals, pulmonologists, surgeons, oncology nurses, nurse practitioners, pharmacists, physician assistants, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with NSCLC.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify and review key oncogenic drivers of NSCLC
    • Integrate guideline-recommended strategies for biomarker analysis in advanced/metastatic NSCLC to identify potentially efficacious targeted therapies
    • Evaluate various biomarker testing methodologies and diagnostic assays to determine mutational status in advanced/metastatic NSCLC
    • Assess evidence for newer targeted therapy and immunotherapy options for the treatment of advanced/metastatic NSCLC with driver mutations
    • Apply evidence-based biomarker-guided therapy for advanced/metastatic NSCLC patients based upon the presence of oncogenic driver mutations
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

    Credit Designation for Pharmacists

    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-026-H01-P.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until July 15, 2023. PAs should only claim credit commensurate with the extent of their participation.

     

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-024-L01-P for June 27, 2023 and JA4008106-0000-23-025-L01-P for June 29, 2023.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by educational funding provided by Amgen.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Jun 2024